- Home
- REBN vs EDSA Comparison
REBN vs EDSA Comparison
Compare REBN & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- EDSA
- Stock Information
- Founded
- REBN 2015
- EDSA 2015
- Country
- REBN United States
- EDSA Canada
- Employees
- REBN N/A
- EDSA N/A
- Industry
- REBN Restaurants
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- EDSA Health Care
- Exchange
- REBN Nasdaq
- EDSA Nasdaq
- Market Cap
- REBN 12.8M
- EDSA 14.7M
- IPO Year
- REBN 2022
- EDSA N/A
- Fundamental
- Price
- REBN $2.61
- EDSA $2.43
- Analyst Decision
- REBN
- EDSA Strong Buy
- Analyst Count
- REBN 0
- EDSA 2
- Target Price
- REBN N/A
- EDSA $13.00
- AVG Volume (30 Days)
- REBN 79.0K
- EDSA 31.0K
- Earning Date
- REBN 08-18-2025
- EDSA 08-08-2025
- Dividend Yield
- REBN N/A
- EDSA N/A
- EPS Growth
- REBN N/A
- EDSA N/A
- EPS
- REBN N/A
- EDSA N/A
- Revenue
- REBN $6,103,732.00
- EDSA N/A
- Revenue This Year
- REBN $335.98
- EDSA N/A
- Revenue Next Year
- REBN N/A
- EDSA N/A
- P/E Ratio
- REBN N/A
- EDSA N/A
- Revenue Growth
- REBN 3.38
- EDSA N/A
- 52 Week Low
- REBN $1.03
- EDSA $1.55
- 52 Week High
- REBN $8.30
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- REBN 47.06
- EDSA 72.37
- Support Level
- REBN $2.40
- EDSA $1.89
- Resistance Level
- REBN $3.10
- EDSA $2.54
- Average True Range (ATR)
- REBN 0.21
- EDSA 0.12
- MACD
- REBN -0.02
- EDSA 0.04
- Stochastic Oscillator
- REBN 30.80
- EDSA 78.46
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.